Eventide Asset Management, LLC Immuno Gen, Inc. Transaction History

Eventide Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $6.69 Million - $16.1 Million	-537,000 Reduced 41.31%	763,000 $22.6 Million
Q2 2023 Aug 15, 2023	BUY	$3.75 - $20.05 $4.88 Million - $26.1 Million	1,300,000 New	1,300,000 $24.5 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $3.15 Million - $5.76 Million	-1,000,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $4.75 Million - $7.5 Million	1,000,000 New	1,000,000 $7.42 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.